Spectrum Pharmaceuticals gets $5M milestone payment, settles with GlaxoSmithKline
13th Nov 2006, 19:00 GMT
Spectrum Pharmaceuticals will receive a $5 million milestone payment under its agreement with Par Pharmaceuticals Companies Inc. for sumatriptan injection, the company said Monday.
Spectrum Pharmaceuticals gets $5M milestone payment, settles with GlaxoSmithKline related news:
- Spectrum Pharmaceuticals gets $5M milestone payment — Latest news from Los Angeles Business from bizjournals
- Spectrum Pharmaceuticals settles with GlaxoSmithKline — bizjournals.com Health Care:Pharmaceuticals headlines
- Spectrum Pharmaceuticals to Receive $5 Million Milestone Payment From PAR Pharmaceutical for Sumatriptan Injection — RedOrbit News - Health
- Spectrum Pharmaceuticals to Receive $5 mln Milestone Payment From PAR Pharmaceutical for Sumatriptan Injection — Pharmaceuticals News from StratCenter.com
- Spectrum Says It Reaches Glaxo Settlement — Pharmaceuticals News from StratCenter.com
- Spectrum Pharmaceuticals verkündet Vergleichsvereinbarung mit GlaxoSmithKline im Patentstreit um Imitrex(R)-Injektion — Presseportal
- Spectrum Pharmaceuticals Announces Agreement With GlaxoSmithKline to Settle Imitrex(R) Injection Patent Litigation Spectrum Filed ANDA With Paragraph IV Certification for Sumatriptan Injection in October 2004 and Received Tentative Approval From the FDA in October 2006 — mysan.de - Lifestyle News
- Spectrum Pharmaceuticals Announces Agreement With GlaxoSmithKline to Settle Imitrex Injection Patent Litigation — Government/ Industry Regulation News from StratCenter.com
- Spectrum Pharmaceuticals wird auf dem Kongress der Société Internationale d'Urologie Ergebnisse zu Ozarelix vorstellen — Presseportal.de Finanzen
- Medarex to Receive Milestone Payment from Amgen — Bio-Technology News from StratCenter.com
Latest news from bizjournals.com Health Care:Pharmaceuticals headlines:
- Corautus Genetics chips at Q3 loss
- Spherix hoping to brush its sweet tooth
- Auxilium added to NASDAQ's biotech index
- CombinatoRx reports revenue boost
- Alexion gets fast-track FDA review for drug Soliris
- InnoCentive identifies a new CEO
- Digene names new CEO
- Dynamic Health dips into the red
- Sigma-Aldrich elects Paul to board
- CollaGenex to net $43M from stock sale